drugset / Trial / NCT02199678

A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction

NCT02199678

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2, randomized, multicenter, parallel group, double-blind, dose-ranging, placebo-controlled evaluation of the analgesic efficacy, safety and pharmacokinetics of ketamine sublingual wafer in adult subjects who experience post operative pain after undergoing third molar extraction.

Timeline

Start
2014-07
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 25 mg Other
Comparator Ketamine Small molecule 35 mg Other
Comparator Ketamine Small molecule 50 mg Other

Indications

No indication recorded.